ImageneBio CEO granted options and RSUs

ImageneBio, Inc. reported that Chief Executive Officer Kristin Yarema received new equity awards as part of her compensation.

Accepted by SEC EDGAR 03/18/2026 - 06:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ImageneBio, Inc. reported that Chief Executive Officer Kristin Yarema received new equity awards as part of her compensation. She was granted an option to buy 128,100 shares of common stock at an exercise price of $6.20 per share, vesting over four years starting March 15, 2027. She also received 85,400 restricted stock units, each convertible into one share of common stock, with 25% vesting on March 15, 2027 and the rest in equal quarterly installments over the following three years, subject to continued service.

Insider Trade Summary

Grant/Award: 213,500 shares

Grant/Award 2 txns

Insider Yarema Kristin

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	128,100	$0.00	$0.00
Grant/Award	Common Stock	85,400	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 128,100 contracts (Direct); Common Stock — 85,400 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on March 15, 2027, and the balance will vest in successive equal quarterly installments on each of the next 12 Standard Quarterly Dates thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan")) through each such vesting date. The "Standard Quarterly Dates" are each of March 15, June 15, September 15 and December 15.
2. F2. This option vests over four years, with 25% of the shares subject to this option vesting on March 15, 2027, and the remaining shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2025 Plan) through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did ImageneBio (IMA) CEO Kristin Yarema receive?

Kristin Yarema received an option for 128,100 shares at $6.20 per share and 85,400 restricted stock units. These grants increase her long-term equity-based compensation, aligning her interests with ImageneBio shareholders through multi-year vesting tied to continued service.

How do Kristin Yarema’s new stock options at ImageneBio (IMA) vest?

The 128,100-share stock option vests over four years. Twenty-five percent vests on March 15, 2027, with the remaining shares vesting in 36 substantially equal monthly installments thereafter, contingent on her continued service under ImageneBio’s 2025 Equity Incentive Plan.

What are the vesting terms for the 85,400 RSUs granted by ImageneBio (IMA)?

The 85,400 restricted stock units vest over approximately four years. Twenty-five percent vest and settle into common stock on March 15, 2027, with the remaining RSUs vesting in equal quarterly installments over the next 12 Standard Quarterly Dates, subject to continued service.

What does the $6.20 exercise price mean for ImageneBio (IMA) CEO’s option grant?

The $6.20 exercise price means Kristin Yarema can buy ImageneBio common shares at $6.20 once options vest. Any potential value depends on the market price exceeding $6.20 when she chooses to exercise, after vesting and subject to plan conditions.

Are Kristin Yarema’s new ImageneBio (IMA) awards open-market purchases?

No. Both transactions are compensation-related grants. The Form 4 classifies them under code A as grant or award acquisitions, with zero purchase price per share, rather than open-market buying or selling of ImageneBio common stock by the CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yarema Kristin

(Last) (First) (Middle)

C/O IMAGENEBIO, INC.

12526 HIGH BLUFF DRIVE, SUITE 345

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImageneBio, Inc. [ IMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		A		85,400(1)	A	$0	85,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$6.2	03/16/2026		A		128,100		(2)	03/16/2036	Common Stock	128,100	$0	128,100	D

Explanation of Responses:

1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on March 15, 2027, and the balance will vest in successive equal quarterly installments on each of the next 12 Standard Quarterly Dates thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan")) through each such vesting date. The "Standard Quarterly Dates" are each of March 15, June 15, September 15 and December 15.

2. This option vests over four years, with 25% of the shares subject to this option vesting on March 15, 2027, and the remaining shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2025 Plan) through each such vesting date.

	/s/ Kristin Yarema	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)